Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators ... is based on research showing the medicine, called inavolisib, could offer a ...

Roche's Itovebi was the first PI3K inhibitor to get approved ... has an FDA green light as part of a combination regimen for patients with advanced HR-positive, HER2-negative breast cancer with ...

Roche RHHBY announced that the FDA has approved pipeline candidate, inavolisib, for the treatment of breast cancer ... based regimen was granted Priority Review by the FDA. It was also granted ...

Two promising candidates in Roche’s breast cancer pipeline are giredestrant and inavolisib, among others. Inavolisib is currently under review in ... recently won FDA approval for Kisqali ...

Roche Holding said the U.S. Food and Drug Administration granted priority review to the company's new drug application for inavolisib as a treatment for a type of advanced breast cancer.